CARsgen Eyes US Filing For Anti-Claudin18.2 CAR-T Therapy
Chinese start-up CARsgen Therapeutics hopes to launch trials in the US for its first-in-class anti-claudin18.2 CAR-T cell therapy. It is also looking at a new round of fundraising to support multiple clinical development programs.
You may also be interested in...
Venture Capital Edition: A VC investor at a recent conference said it's "hogwash" that venture capitalists aren't interested in funding early-stage biopharma, but the trend toward large financings – such as the $220m raised to date by Rubius – and 2017 investment data suggest otherwise.
Novartis got a leg up on its competition Aug. 30 with an earlier-than-expected approval for Kymriah in pediatric ALL, ending the CAR-T pricing mystery with its $475,000 price tag, which the company is positioning as a relative bargain.
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.